Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For a connected medical device, such as a wireless patient monitor or a software-as-a-medical-device (SaMD) application, how should a sponsor structure the cybersecurity documentation within a premark...
How should a medical device manufacturer, particularly one without a physical establishment in the EU or UK, develop a comprehensive strategy for selecting a WEEE/EPR authorized representative or comp...
For in vitro diagnostic (IVD) devices, what key factors differentiate a moderate-risk Class II device, which is often subject to special controls, from a high-risk Class III device that requires a Pre...
For manufacturers of electrical and electronic medical devices, navigating environmental compliance regulations like the Waste from Electrical and Electronic Equipment (WEEE) Directive and Extended Pr...
For medical device manufacturers, particularly small to medium-sized enterprises (SMEs) or those based outside the European Union, engaging a "PRRC as a Service" provider is a common strategy to fulfi...
When evaluating external "PRRC as a Service" providers for 2025 budgets, medical device manufacturers find that pricing is not standardized and can vary significantly. Instead of a fixed cost, the fee...
When evaluating 'Person Responsible for Regulatory Compliance (PRRC) as a Service' providers under the EU MDR, how can a medical device manufacturer move beyond comparing simple monthly retainers to a...
Given the European Union's advancing restrictions on per- and polyfluoroalkyl substances (PFAS) under REACH, what is the comprehensive due diligence process for a non-EU medical device manufacturer to...
For non-EU medical device manufacturers, selecting an EU Authorized Representative (AR) is a critical requirement for compliance with the Medical Device Regulation (MDR) and In Vitro Diagnostic Regula...
When a company plans to import chemical substances or mixtures into the European Union that are subject to REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals), they often appo...
When developing a prescription software device intended to analyze ophthalmic images for diagnostic purposes, how can sponsors effectively navigate the regulatory requirements associated with the "ret...
As non-EU businesses prepare for the significant 2026 changes to France's VAT rules, particularly regarding Regime 42, what constitutes a robust, step-by-step process for selecting, appointing, and ma...
When developing a novel diagnostic software device, such as one that analyzes medical images, what are the key considerations for establishing a regulatory strategy under FDA's framework? For instance...
With the landscape of environmental compliance evolving, particularly with new WEEE (Waste Electrical and Electronic Equipment) and EPR (Extended Producer Responsibility) regulations taking effect in ...
With significant environmental compliance reforms like the WEEE Directive evolving and new national Extended Producer Responsibility (EPR) requirements anticipated for 2025, how can medical device man...
As global environmental regulations evolve, how should medical device manufacturers, particularly those producing devices with electrical or electronic components, develop a strategy for managing end-...
With significant revisions to the primary international standard for the biological evaluation of medical devices anticipated for 2026, how should manufacturers proactively adapt their biocompatibilit...
With significant updates to key biocompatibility standards, including the ISO 10993 series, anticipated around 2026, how should manufacturers of devices with patient-contacting components proactively ...
As international biocompatibility standards evolve, medical device manufacturers face uncertainty in planning their testing strategies, particularly for devices with long development cycles. Selecting...
For a non-U.S. medical device manufacturer planning for 2026 market entry, what are the key strategic considerations beyond basic fees when selecting a U.S. Agent, particularly for devices with signif...